Bo Wang

ORCID: 0000-0002-3307-6058
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Bladder and Urothelial Cancer Treatments
  • Immune Response and Inflammation
  • Immune cells in cancer
  • Immunotherapy and Immune Responses
  • Mycobacterium research and diagnosis
  • Immune Cell Function and Interaction
  • Urinary and Genital Oncology Studies
  • Ferroptosis and cancer prognosis
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Multiple and Secondary Primary Cancers
  • Hematological disorders and diagnostics
  • Cancer-related molecular mechanisms research
  • Tissue Engineering and Regenerative Medicine
  • Epigenetics and DNA Methylation
  • Multiple Myeloma Research and Treatments
  • Orthopedic Surgery and Rehabilitation
  • Electrospun Nanofibers in Biomedical Applications
  • Orthopedic Infections and Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Cancer Mechanisms and Therapy
  • RNA modifications and cancer
  • Bone fractures and treatments
  • Protein Degradation and Inhibitors
  • Pelvic and Acetabular Injuries

Sun Yat-sen Memorial Hospital
2015-2025

Sun Yat-sen University
2015-2025

Zhejiang Chinese Medical University
2024-2025

Center for Cancer Research
2025

Harvard University
2025

Massachusetts General Hospital
2025

Willamette Valley Cancer Institute and Research Center
2023-2024

Kunming Medical University
2023

Suzhou Kowloon Hospital
2021-2022

Shanghai Jiao Tong University
2021

CD8(+) TILs at different tumor sites have diverse clinical attributes, which might result from distinct microenvironments that promote differentiation into subsets. However, only a few markers been identified can define T-cell CD103 is marker of tissue resident memory T cells. In this retrospective study we investigated the cellular source and significance expression in urothelial cell carcinoma bladder tissues situ.Immunohistochemistry immunofluorescence were used to identify tissues....

10.1016/j.juro.2015.02.2941 article EN The Journal of Urology 2015-03-06

Drugs blocking programmed death ligand‐1 ( PD ‐L1) have shown unprecedented activity in metastatic and unresectable bladder cancer. The purpose of the present study was to investigate expression, clinical significance association ‐L1 with tumor‐infiltrating lymphocytes TIL ) resectable urothelial cell carcinoma UCB ). In this retrospective study, 248 patients who received radical cystectomy or transurethral resection were examined. Immunohistochemistry used evaluate expression stromal CD 8 +...

10.1111/cas.13887 article EN cc-by-nc Cancer Science 2018-12-12

Activation of PI3K/AKT signalling by PTEN loss significantly enhances chemoresistance in bladder cancer. This study aims to evaluate regulation and identify targets that could be used relieve chemoresistance. Expression YTHDC1, γ-H2AX were detected IHC assay. Cell Counting Kit-8 assay, colony formation assay tumour xenograft experiment evaluated cisplatin response. Flow cytometry comet estimated cell apoptosis, cycle distribution DNA repair capability. Quantitative real-time polymerase chain...

10.1111/cpr.13404 article EN cc-by Cell Proliferation 2023-04-17

CD4+ T cells contribute to antitumor immunity and are implicated in the efficacy of cancer immunotherapies. In particular, helper 2 (Th2) were recently found block spontaneous breast carcinogenesis. However, potential Th2 targeting established remains uncertain. Herein, we demonstrate that induced by topical calcipotriol/thymic stromal lymphopoietin cytokine axis suppressed growth mammary tumors mice. Interleukin-24 (IL-24), an anticancer cytokine, was highly upregulated macrophages...

10.1172/jci.insight.180962 article EN cc-by JCI Insight 2025-01-08

Background Interferons (IFNs) are essential for activating an effective immune response and play a central role in immunotherapy-mediated cell reactivation tumor regression. Type III IFN (λ), related to type I (α), plays crucial infections, autoimmunity, cancer. However, the direct effects of IFN-λ on microenvironment have not been thoroughly investigated. Methods We used mouse MB49 bladder models, constructed retroviral vector expressing IFN-λ3, transduced cells evaluate antitumor action...

10.1136/jitc-2023-007808 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2024-04-01

The tumor microenvironment (TME) plays a critical regulatory role in bladder cancer (BLCA) progression and metastasis. Epithelial-mesenchymal transition (EMT) presents as an essential mechanism of invasion Accumulating pieces evidence indicated that several microenvironmental factors, including fibroblasts, endothelial, immune cells, induced EMT cells. As hallmark gene the process, calumenin (CALU) was previously reported to directly impact However, functions molecular mechanisms CALU have...

10.3389/fonc.2021.683951 article EN cc-by Frontiers in Oncology 2021-06-03

Background This study comprehensively investigates the association between expression of nicotinamide N-methyltransferase (NNMT) and clinical outcomes urothelial bladder cancer (UBC), as well molecular mechanisms by which NNMT in cancer-associated fibroblast (CAF) modulates tumor progression immunotherapy resistance UBC. Methods Single-cell transcriptomic analyses, immunohistochemical immunofluorescence assays were performed on samples to validate relationship outcomes. A series experiments,...

10.1136/jitc-2024-009281 article EN cc-by-nc-nd Journal for ImmunoTherapy of Cancer 2024-07-01

Objectives To evaluate the prognostic value of Molecular International Prognostic Scoring System (IPSS-M) compared to Revised (IPSS-R) in patients with myelodysplastic neoplasms (MDS) Jiangnan region China.

10.1080/16078454.2025.2479257 article EN cc-by Hematology 2025-03-17

Despite the widespread use of carfilzomib (K) in relapsed/refractory multiple myeloma (RRMM), there is no consensus on optimal K dose milligrams per square meter (mg/m2) or dosing schedule. We assessed three modern prescribing patterns RRMM using a large United States electronic health record-derived database. Our final cohort (n = 486) included 136 patients (28.0%) who received 56 mg/m2 once weekly (K56-1x), 86 (17.7%) twice (K56-2x), and 264 (54.3%) 70 (K70-1x). Between 2016 2023,...

10.1038/s41408-025-01256-2 article EN cc-by-nc-nd Blood Cancer Journal 2025-03-28

// Li Huang 1,2 , Yang Peng Guangzheng Zhong Weibin Xie Wen Dong Bo Wang Xu Chen Gu He Shaoxu Wu Tianxin Lin and Jian 1 Department of Urology, Sun Yat-Sen Memorial Hospital, University, Guangzhou 510120, China 2 Guangdong Provincial Key Laboratory Malignant Tumor Epigenetics Gene Regulation, Correspondence to: Lin, email: Huang, Keywords : bladder cancer, PBRM1, cell cycle, cyclin B1 Received February 03, 2015 Accepted April Published 19, Abstract Growing evidence indicates that...

10.18632/oncotarget.3879 article EN Oncotarget 2015-04-19

Locally advanced upper urinary tract urothelial carcinoma (UTUC) exhibits high recurrence and metastasis rates even after radical nephroureterectomy. Adjuvant immunotherapy can be a reasonable option, simple, low-cost, effective biomarker is further needed. Stromal tumor-infiltrating lymphocytes (sTILs) has been demonstrated as prognostic predictive in various tumor types, but not yet locally UTUC. In this multicenter, real-world retrospective study, we tried to investigate the role of sTIL...

10.1080/2162402x.2020.1861737 article EN cc-by-nc OncoImmunology 2021-01-01

Bladder cancer (BLCA) is a tumor that possesses significant heterogeneity, and the microenvironment (TME) plays an important role in development of BLCA. The TME chiefly consists cells tumor-infiltrating immune admixed with stromal components. Recent studies have revealed components, especially cancer-associated fibroblasts (CAFs), affect cell infiltration modulate extracellular matrix BLCA, ultimately impacting prognosis therapeutic efficacy Among subgroups CAFs, myofibroblasts (myCAFs)...

10.3389/fcell.2022.833578 article EN cc-by Frontiers in Cell and Developmental Biology 2022-03-02

Abstract Resistance to anti–PD-1/PD-L1 treatment is often associated with accumulation of intratumoral inhibitory macrophages. V-domain immunoglobulin suppressor T-cell activation (VISTA) a nonredundant immune checkpoint that can induce both and myeloid-cell immunosuppression. In this study, we found high levels VISTA+ cells were advanced stage bladder cancer predicted poor survival in patients. A combination infiltration PD-L1+ or PD-1+ T the worst survival. Flow cytometry multiplex...

10.1158/2326-6066.cir-23-0117 article EN Cancer Immunology Research 2023-10-17

The prediction of the response to Bacillus Calmette-Guerin (BCG) can help identify non-muscle-invasive bladder cancer (NMIBC) patients that may be better served with alternative therapy. Several cytokine profiles present promising results, but they are difficult use in clinical practice. In this prospective, longitudinal study, we tried reliable serum cytokines/chemokines predict BCG using samples collected before and during induction We used Bio-plex multiplex assays potential...

10.1080/2162402x.2020.1776060 article EN cc-by-nc OncoImmunology 2020-01-01

<title>Abstract</title> <bold>Objectives</bold> The Revised international prognostic scoring system (IPSS-R) is now commonly being used clinically to guide the treatment of myelodysplastic neoplasms (MDS). Recently, Molecular International Prognostic Scoring System (IPSS-M)was proposed. In this study, we have validated potential predictive value comparative IPSS-M in Chinese MDS patients. <bold>Design</bold> Retrospective multicenter observational study. <bold>Setting and participants</bold>...

10.21203/rs.3.rs-4129078/v1 preprint EN cc-by Research Square (Research Square) 2024-03-25

Lymphatic metastasis, an early stage of the metastasis process, is associated with adverse clinical outcomes in urothelial carcinoma bladder (UCB). However, role inflammation triggering lymphatic remains unclear. We employed RNA-sequencing cohort (n = 50) from Sun Yat-Sen Memorial Hospital (SYMH) to identify most highly upregulated inflammatory gene metastasis. Using immunohistochemistry and immunofluorescence analyses, we validated association identified molecule features prognosis...

10.1002/cti2.1505 article EN cc-by-nc-nd Clinical & Translational Immunology 2024-01-01
Coming Soon ...